Acylated Active Agents Modulate Autoimmunity Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders, such as inflammatory bowel disease, often come with undesirable side effects and risks, necessitating the development of new therapeutic approaches that can effectively modulate autoimmunity markers without these drawbacks.
Innovation Solution
The use of acylated active agents, including acylated catechin polyphenols, mesalamines, sugars, hydroxybenzoic acids, and shikimic acids, which are administered to modulate autoimmunity markers by acting synergistically with the host's immune system, potentially reducing inflammation and improving symptoms in autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroid and immunosuppressant therapies are used to treat inflammatory bowel disease, then anti-inflammatory effect is improved, but side effects and comorbidity risks increase
Solution Approach 1:
The patent applies parameter changes by acylating active agents with different chain lengths and degrees of unsaturation to modulate their anti-inflammatory activity and immune-modulating properties. This chemical modification allows tuning of the therapeutic parameters to achieve effective treatment with reduced toxicity compared to conventional steroids and immunosuppressants.
Solution Approach 2:
The invention uses composite materials by combining active agents with fatty acid moieties to create acylated derivatives that exhibit synergistic effects. These composite molecules integrate the anti-inflammatory properties of the active agent with the immune-modulating capabilities of fatty acids, providing enhanced therapeutic efficacy with fewer side effects.
2Object-affected harmful factors
If new therapeutic approaches are developed to avoid side effects, then safety is improved, but treatment efficacy may be compromised
Solution Approach 1:
The patent applies dynamics by creating a series of acylated derivatives with varying chain lengths and unsaturation levels, allowing the therapeutic effect to be dynamically adjusted. This enables optimization of the balance between safety and efficacy by selecting the appropriate derivative for each patient's specific condition and severity.
Solution Approach 2:
By systematically varying the fatty acid parameters (chain length, degree of unsaturation), the invention creates a gradient of therapeutic agents with progressively modulated effects. This parameter optimization allows achieving maximum safety without compromising necessary treatment efficacy.
Data Source
AI summary
Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.